Literature DB >> 9337062

Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses.

S Neu1, A Geiselhart, M Sproll, D Hahn, S Kuçi, D Niethammer, R Handgretinger.   

Abstract

CD34-positive cells were isolated from cord blood (n = 8), bone marrow (n = 4) and leukapheresed material (n = 7), using an immunomagnetic isolation technique, MACS (Miltenyi Biotec, Bergisch Gladbach, Germany). In flow cytometric analysis, cell populations after enrichment revealed a fraction of 96.1% (cord blood), 96.2% (bone marrow) and 98.6% (leukapheresis material) CD34-positive cells. Cells were further stained with antibodies specific for CD44 isoforms: CD44s (SFF-2), CD44v5 (VFF-8) and CD44v6 (VFF-18). CD44-positive cells were detected by directly (FITC, fluorescein isothiocyanate) or indirectly (streptavidin-PE, phycoerythrin)-conjugated fluorochromes in flow cytometric analysis. Analysis was restricted to CD34-positive cells. A high expression of CD44s was noted in all kinds of material under investigation with mean values in the range of 98.6-100%. There was little expression of CD44v6 (mean values in the range of 1.5-3.6%) and very slight expression of CD44v5 (mean values in the range of 0.6-1.4%). The finding that CD34-positive hematopoietic stem cells express CD44v5 and CD44v6 to a very small extent offers the possibility of using antibodies specific to CD44v5 and CD44v6 in immunopurging in the course of autologous stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337062     DOI: 10.1038/sj.bmt.1700940

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

Review 1.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 2.  Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Zaid Mahdi Jaber Al-Obaidi; Abduladheem Turki Jalil; Walid Kamal Abdelbasset; Wanich Suksatan; Aleksei Evgenievich Dorofeev; Navid Shomali; Max Stanley Chartrand; Yashwant Pathak; Ali Hassanzadeh; Behzad Baradaran; Majid Ahmadi; Hossein Saeedi; Safa Tahmasebi; Mostafa Jarahian
Journal:  Stem Cell Res Ther       Date:  2021-08-20       Impact factor: 6.832

3.  Two different functions for CD44 proteins in human myelopoiesis.

Authors:  J Moll; S Khaldoyanidi; J P Sleeman; M Achtnich; I Preuss; H Ponta; P Herrlich
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 4.  T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.

Authors:  Naval Daver; Ahmad S Alotaibi; Veit Bücklein; Marion Subklewe
Journal:  Leukemia       Date:  2021-05-05       Impact factor: 11.528

5.  Transcriptomics of the late gestation ovine fetal brain: modeling the co-expression of immune marker genes.

Authors:  Maria B Rabaglino; Maureen Keller-Wood; Charles E Wood
Journal:  BMC Genomics       Date:  2014-11-19       Impact factor: 3.969

Review 6.  Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.

Authors:  Maria Castella; Carlos Fernández de Larrea; Beatriz Martín-Antonio
Journal:  Int J Mol Sci       Date:  2018-11-15       Impact factor: 5.923

Review 7.  Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).

Authors:  Susanne Hofmann; Maria-Luisa Schubert; Lei Wang; Bailin He; Brigitte Neuber; Peter Dreger; Carsten Müller-Tidow; Michael Schmitt
Journal:  J Clin Med       Date:  2019-02-06       Impact factor: 4.241

Review 8.  Cell-based immunotherapy approaches for multiple myeloma.

Authors:  Katharina Kriegsmann; Mark Kriegsmann; Martin Cremer; Michael Schmitt; Peter Dreger; Hartmut Goldschmidt; Carsten Müller-Tidow; Michael Hundemer
Journal:  Br J Cancer       Date:  2018-12-06       Impact factor: 7.640

Review 9.  Dendritic cell-based immunotherapy for myeloid leukemias.

Authors:  Christian M Schürch; Carsten Riether; Adrian F Ochsenbein
Journal:  Front Immunol       Date:  2013-12-31       Impact factor: 7.561

Review 10.  Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.

Authors:  Paolo Bernasconi; Oscar Borsani
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.